文献速递免疫规划传染病防控与疫情报告

日本婴儿RSV住院预防:季节性免疫与全年免疫的建模研究

Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study.
PubMed 文献 · Vaccine · 2026-08-26

该建模研究比较了日本婴儿RSV预防中季节性+补种免疫与全年免疫策略的效果。全年RSVpreF或nirsevimab分别可减少46%或58%的RSV住院,季节性+补种方案分别减少52%或57%。若RSV季节性与免疫时机匹配,季节性方案效果更优。

要点

  • 全年nirsevimab可减少58% RSV住院,优于RSVpreF的46%。
  • 季节性+补种方案与全年方案效果相当,取决于RSV季节性预测。
  • nirsevimab保护若持续超过6个月,全年方案可能更有效。

核心结论

  • RSVpreF和nirsevimab可大幅减少日本婴儿RSV住院。
  • 季节性+补种方案获益取决于RSV季节性可预测性和后勤挑战。

研究设计与样本

  • 静态队列模型,随访婴儿至1岁,参数基于2018-2025年日本周和市町村RSV发病率及住院风险数据。
  • 采用贝叶斯推断从试验数据估计RSVpreF和nirsevimab的有效性及衰减。

主要发现

  • 全年RSVpreF方案减少RSV住院46%(95% UR: 31%, 65%),全年nirsevimab减少58%(95% UR: 39%, 79%)。
  • 季节性+补种方案分别减少52%(95% UR: 37%, 65%)和57%(95% UR: 38%, 75%)。
  • 若季节性与免疫时机匹配(以2024年为例),季节性+补种方案分别减少56%(95% UR: 46%, 67%)和61%(95% UR: 44%, 77%)。
  • 若nirsevimab保护在6个月后仍显著,全年方案可能更有效。

临床怎么用

  • 可根据RSV季节性选择季节性+补种或全年免疫策略。
  • 需考虑nirsevimab保护持续时间对策略选择的影响。

局限性

  • 模型为静态队列,可能未完全捕捉动态传播效应。
  • 季节性方案效果依赖于RSV季节性的可预测性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The seasonal circulation of respiratory syncytial virus (RSV) in countries such as Japan, together with the transient nature of passive immunity conferred to infants via maternal vaccination or monoclonal antibody administration, may warrant a differential strategy for those born between the RSV seasons. Maximal effectiveness may be achieved by deferring immunisation of this cohort from birth until entry into their first RSV season using catch-up administration of monoclonal antibody through a seasonal and catch-up programme, compared with year-round administration. To estimate the benefit of seasonal and catch-up programmes in reducing RSV infant hospitalisations in Japan, we developed a static cohort model following infants through their first year of life, parameterised by Japanese data on weekly and municipality-specific RSV incidence during 2018 to 2025 and on RSV case hospitalisation risk from a health claims database study. We used Bayesian inference to estimate the effectiveness and its waning for maternal vaccine (RSVpreF) and long-acting monoclonal antibody (nirsevimab) from trial data. We estimate that year-round programme of RSVpreF or nirsevimab could reduce RSV hospitalisations from the status quo, under which only high-risk infants are eligible for monoclonal antibodies, by 46% (95% uncertainty range (UR): 31%, 65%) or 58% (95% UR: 39%, 79%), respectively. In comparison, the seasonal and catch-up programme could reduce by 52% (95% UR: 37%, 65%) or 57% (95% UR: 38%, 75%), respectively. If seasonality matches the seasonal immunisation timing, using 2024 as an example, the reduction by the seasonal and catch-up programme would be 56% (95% UR: 46%, 67%) or 61% (95% UR: 44%, 77%), respectively. If protection from nirsevimab remained substantial after six months, the year-round programme would likely to be more effective. RSVpreF and nirsevimab may substantially reduce RSV infant hospitalisations in Japan. The benefit of the seasonal programmes depends on predictability of RSV seasonality and potential logistical challenges.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Monoi A, Endo A, Kriznar M, et al. Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study. Vaccine. 2026. PMID: 42648051. doi:10.1016/j.vaccine.2026.129079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。